Asset profile

Ivonescimab

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2027-05.

NCT04900363: The study assigned all participants to ivonescimab without randomization, blinding, or a comparison arm. Although its primary outcomes included clinical measures such as RECIST-based objective response and progression-free survival, no results have been posted, so the treatment effect cannot be evaluated.

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(47 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (5)

August 2026 (1)

Phase 2Breast CancerRecruiting

Est. primary completion 2026-08-31 · NCT06402435 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (4)

Phase 3Triple-Negative Breast Cancer (TNBC)Recruiting

Est. primary completion 2026-12 · NCT06767527 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2026-12-30 · NCT07086326 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast CancerActive not recruiting

Est. primary completion 2026-12-30 · NCT05227664 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-12-31 · NCT06769295 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (21)

January 2027 (1)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-01 · NCT07208773 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (1)

Phase 2KRAS G12C Lung CancerNot yet recruiting

Est. primary completion 2027-04-30 · NCT06936644 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (3)

Phase 2Squamous Cell Lung CancerNot yet recruiting

Est. primary completion 2027-05 · NCT07009925 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-05 · NCT06928389 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-05-30 · NCT07590531 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-07-01 · NCT07630077 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-08-30 · NCT07669779 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (3)

Phase 2Advanced Breast CancerRecruiting

Est. primary completion 2027-09-01 · NCT07591090 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-09-30 · NCT07339839 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metastatic Endocrine Refractory, Triple Negative Invasive Lobular CarcinomaRecruiting

Est. primary completion 2027-09-30 · NCT07229417 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-10 · NCT07204548 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-11-30 · NCT07241819 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (9)

Phase 2TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast CarcinomaRecruiting

Est. primary completion 2027-12 · NCT07017673 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-01 · NCT06684873 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-30 · NCT07603791 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast CancerRecruiting

Est. primary completion 2027-12-30 · NCT07647016 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-31 · NCT07472478 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-31 · NCT07489703 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer - FemaleNot yet recruiting

Est. primary completion 2027-12-31 · NCT07103447 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting

Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-31 · NCT07742956 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (16)

January 2028 (1)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2028-01-01 · NCT07669051 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (3)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-03-01 · NCT07405190 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-03-31 · NCT07412262 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metastatic Breast Cancer ( HER2 Negative), ctDNARecruiting

Est. primary completion 2028-03-31 · NCT07394218 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (3)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-04 · NCT07535437 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-04 · NCT07535463 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-04 · NCT06767514 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-05-12 · NCT07594522 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (2)

Phase 1/2Breast CancerNot yet recruiting

Est. primary completion 2028-06-06 · NCT07560124 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-06-18 · NCT07623356 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-07 · NCT07158489 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-07-01 · NCT06951646 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-09 · NCT07158840 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)

Phase 2Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Not yet recruiting

Est. primary completion 2028-11-30 · NCT07393555 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (2)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-12-31 · NCT05899608 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Small Cell Lung CancerRecruiting

Est. primary completion 2028-12-31 · NCT07010263 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (2)

January 2029 (1)

Phase 2TNBC, Triple Negative Breast CancerNot yet recruiting

Est. primary completion 2029-01 · NCT06977542 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (1)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-05 · NCT07397338 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)

December 2030 (1)

Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting

Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (2)

January 2032 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2032-01 · NCT07234877 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2032 (1)

Phase 2Breast Cancer, Triple Negative Breast CancerNot yet recruiting

Est. primary completion 2032-12 · NCT07743632 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.